Surging higher....TSRX is in the first inning. The game/run has just begun.
Tuesday, May 14, 11:39 AM ET
Shares of Trius Therapeutics (TSRX +5.6%) gain this morning after the company announced late yesterday that it's received a Notice of Allowance from the USPTO on an application related to its tedizolid phosphate patent portfolio. The new application protects a therapeutic combination of the experimental medicine with a currently available antibiotic daptomycin. Together, TSRX claims the medicines can prevent the development of certain strains of staph infection.